FI3607962T3 - Angiotensiini ii yksin tai yhdistelmänä hypotension hoitoon - Google Patents

Angiotensiini ii yksin tai yhdistelmänä hypotension hoitoon

Info

Publication number
FI3607962T3
FI3607962T3 FIEP19197866.7T FI19197866T FI3607962T3 FI 3607962 T3 FI3607962 T3 FI 3607962T3 FI 19197866 T FI19197866 T FI 19197866T FI 3607962 T3 FI3607962 T3 FI 3607962T3
Authority
FI
Finland
Prior art keywords
composition
use according
angiotensin
catecholamine
vasopressin
Prior art date
Application number
FIEP19197866.7T
Other languages
English (en)
Finnish (fi)
Inventor
Lakhmir Chawla
Original Assignee
The George Washington Univ A Congressionally Chartered Not For Profit Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53367119&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI3607962(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by The George Washington Univ A Congressionally Chartered Not For Profit Corporation filed Critical The George Washington Univ A Congressionally Chartered Not For Profit Corporation
Application granted granted Critical
Publication of FI3607962T3 publication Critical patent/FI3607962T3/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/085—Angiotensins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
FIEP19197866.7T 2013-12-18 2014-12-18 Angiotensiini ii yksin tai yhdistelmänä hypotension hoitoon FI3607962T3 (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361917576P 2013-12-18 2013-12-18
US201461955706P 2014-03-19 2014-03-19

Publications (1)

Publication Number Publication Date
FI3607962T3 true FI3607962T3 (fi) 2025-11-24

Family

ID=53367119

Family Applications (1)

Application Number Title Priority Date Filing Date
FIEP19197866.7T FI3607962T3 (fi) 2013-12-18 2014-12-18 Angiotensiini ii yksin tai yhdistelmänä hypotension hoitoon

Country Status (25)

Country Link
US (7) US9220745B2 (enExample)
EP (2) EP2986308B1 (enExample)
JP (4) JP6824739B2 (enExample)
KR (4) KR102399383B1 (enExample)
CN (4) CN106061493A (enExample)
AU (3) AU2014364528C1 (enExample)
BR (1) BR112016013961A2 (enExample)
CA (1) CA2933601A1 (enExample)
CY (1) CY1122604T1 (enExample)
DK (2) DK3607962T3 (enExample)
EA (1) EA037823B1 (enExample)
ES (1) ES2771749T3 (enExample)
FI (1) FI3607962T3 (enExample)
HR (1) HRP20200009T1 (enExample)
HU (1) HUE047062T2 (enExample)
IL (1) IL246162B (enExample)
LT (2) LT3607962T (enExample)
MX (2) MX380968B (enExample)
NZ (1) NZ721089A (enExample)
PL (1) PL2986308T3 (enExample)
PT (2) PT3607962T (enExample)
RS (1) RS59804B1 (enExample)
SI (1) SI2986308T1 (enExample)
SM (2) SMT202000018T1 (enExample)
WO (1) WO2015095535A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9572856B2 (en) 2009-12-16 2017-02-21 The George Washington University a Congressionally Chartered Not-for-Profit Corporation Method of treating low blood pressure
US9220745B2 (en) 2013-12-18 2015-12-29 The George Washington University, a Congressionally Not-for-Profit Corporation Angiotensin II alone or in combination for the treatment of hypotension
KR20170026486A (ko) * 2014-07-08 2017-03-08 라 졸라 파마슈티칼 컴파니 저혈압 치료 방법
US9919022B2 (en) 2015-03-20 2018-03-20 Arthur J. ATKINSON, JR. Use of angiotensin II (AII) receptor agonists to prevent or reduce hemodialysis-associated skeletal muscle cramps
BR112018013847A2 (pt) 2016-01-07 2018-12-18 La Jolla Pharma Co métodos para administrar a angiotensina ii
WO2017120440A1 (en) * 2016-01-07 2017-07-13 La Jolla Pharmaceutical Company Methods of administering vasopressors
WO2018191678A1 (en) * 2017-04-14 2018-10-18 La Jolla Pharmaceutical Company Methods for administering angiotensin ii
WO2019118874A1 (en) * 2017-12-15 2019-06-20 La Jolla Pharma, Llc Angiotensin compositions and methods related thereto
US20250366467A1 (en) * 2022-06-15 2025-12-04 Virginia Commonwealth University Methods for fluid resuscitation of an organ donor
WO2024129057A1 (en) * 2022-12-12 2024-06-20 Proletariat Therapeutics, Inc. Methods of treating cardiac injury

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU181008B (en) 1980-01-18 1983-05-30 Richter Gedeon Vegyeszet Process for producing angiotenzin-ii analogues of antagonistic activity containing sarcosyl-group at the 1-positon,and an alpha-hydroxy-carboxylic acid at the 8-position
US5216025A (en) 1989-09-13 1993-06-01 Board Of Regents, The University Of Texas System Nitric oxide synthesis inhibitors for potentiating the action of pressor agents in certain hypotensive patients
US5444067A (en) 1993-08-30 1995-08-22 Merck & Co., Inc. Pharmaceutical treatment methods using angiotensin II receptor agonists bearing a thiophene moiety
EP1401864A1 (en) 2001-06-04 2004-03-31 Human Genome Sciences Methods and compositions for modulating ace-2 activity
US7115266B2 (en) 2001-10-05 2006-10-03 Cytos Biotechnology Ag Angiotensin peptide-carrier conjugates and uses thereof
JP2007510643A (ja) 2003-11-06 2007-04-26 ジーイー・ヘルスケア・アクスイェ・セルスカプ 医薬化合物
NO20034952D0 (no) 2003-11-06 2003-11-06 Amersham Health As Farmasöytiske forbindelser
FR2880807B1 (fr) * 2005-01-19 2007-04-13 Aguettant Sa Lab Composition pharmaceutique injectable
DE602006021600D1 (de) 2005-09-29 2011-06-09 Fibrogen Inc Verfahren zur senkung des blutdrucks
AU2006332449B2 (en) 2005-12-30 2008-05-15 Howard Florey Institute Of Experimental Physiology And Medicine A method of treatment
WO2007146900A2 (en) 2006-06-15 2007-12-21 Gilead Colorado, Inc. Antihypertensive therapy method
WO2008130217A1 (en) * 2006-08-08 2008-10-30 Applied Nanosystems B.V. Cyclic angiotensin analogs
CA2678131A1 (en) 2006-11-17 2008-05-22 Antoine Andremont Colonic delivery using zn/pectin beads with a eudragit coating.
WO2009009907A1 (en) * 2007-07-18 2009-01-22 The University Of British Columbia Use of vasopressin-receptor agonists for the treatment of septic shock
EP2161030A1 (en) * 2008-09-09 2010-03-10 Rijksuniversiteit te Groningen Oxytocin formulations and uses thereof
AU2009319856A1 (en) 2008-11-28 2010-06-03 Abbvie Inc. Stable antibody compositions and methods for stabilizing same
US9572856B2 (en) 2009-12-16 2017-02-21 The George Washington University a Congressionally Chartered Not-for-Profit Corporation Method of treating low blood pressure
FR2959414B1 (fr) * 2010-04-30 2016-01-08 Luc Quintin Combinaison de molecules aux fins de traitement d'hypotension survenant au cours du choc septique, cardiogenique, ou anaphylactique refractaire, ou hemorragique terminal, apres correction de la volemie et de l'etat de mal asthmatique refractaire
BR112013000744A2 (pt) 2010-07-14 2020-07-14 Cumberland Emerging Technologies, Inc uso de um antagonista de receptor de tromboxana a2 para prevenção ou tratamento de síndrome hepatorrenal,encefalopatia hepática,e doenças associadas
AU2014256944B2 (en) 2013-04-26 2019-06-27 La Jolla Pharma, Llc Compositions and methods for treating renal failure
US9220745B2 (en) 2013-12-18 2015-12-29 The George Washington University, a Congressionally Not-for-Profit Corporation Angiotensin II alone or in combination for the treatment of hypotension
US20150286797A1 (en) 2014-04-02 2015-10-08 David R. Ratto System and method for administering medication
KR20170026486A (ko) 2014-07-08 2017-03-08 라 졸라 파마슈티칼 컴파니 저혈압 치료 방법
WO2017120440A1 (en) 2016-01-07 2017-07-13 La Jolla Pharmaceutical Company Methods of administering vasopressors
BR112018013847A2 (pt) 2016-01-07 2018-12-18 La Jolla Pharma Co métodos para administrar a angiotensina ii
WO2018191678A1 (en) 2017-04-14 2018-10-18 La Jolla Pharmaceutical Company Methods for administering angiotensin ii
WO2019118874A1 (en) 2017-12-15 2019-06-20 La Jolla Pharma, Llc Angiotensin compositions and methods related thereto

Also Published As

Publication number Publication date
KR20220028125A (ko) 2022-03-08
KR20240154702A (ko) 2024-10-25
US11559559B2 (en) 2023-01-24
JP6824739B2 (ja) 2021-02-03
CA2933601A1 (en) 2015-06-25
DK2986308T3 (en) 2020-01-27
KR20160117437A (ko) 2016-10-10
US11096983B2 (en) 2021-08-24
AU2014364528A1 (en) 2016-06-30
US20180193407A1 (en) 2018-07-12
EP3607962B1 (en) 2025-08-13
MX380968B (es) 2025-03-12
AU2014364528C1 (en) 2021-01-07
NZ721089A (en) 2022-10-28
AU2014364528B2 (en) 2020-08-27
US9220745B2 (en) 2015-12-29
MX2020011190A (es) 2020-11-13
AU2020277230A1 (en) 2020-12-24
DK3607962T3 (da) 2025-11-17
US10493124B2 (en) 2019-12-03
WO2015095535A1 (en) 2015-06-25
RS59804B1 (sr) 2020-02-28
KR20230051721A (ko) 2023-04-18
JP2017501154A (ja) 2017-01-12
AU2024219851A1 (en) 2024-10-10
JP2019214610A (ja) 2019-12-19
KR102399383B1 (ko) 2022-05-19
CN119700926A (zh) 2025-03-28
HRP20200009T1 (hr) 2020-03-20
JP7175506B2 (ja) 2022-11-21
CN112546197A (zh) 2021-03-26
BR112016013961A2 (pt) 2017-10-10
AU2014364528A9 (en) 2016-07-28
EA037823B1 (ru) 2021-05-25
HUE047062T2 (hu) 2020-04-28
EP3607962A1 (en) 2020-02-12
SMT202000018T1 (it) 2020-03-13
JP2022137224A (ja) 2022-09-21
CN106061493A (zh) 2016-10-26
JP2025114753A (ja) 2025-08-05
US20190070250A1 (en) 2019-03-07
US20230226141A1 (en) 2023-07-20
LT2986308T (lt) 2020-03-25
PT2986308T (pt) 2020-01-21
US10765722B2 (en) 2020-09-08
CY1122604T1 (el) 2021-03-12
CN111920939A (zh) 2020-11-13
EP2986308B1 (en) 2019-10-16
EP2986308A1 (en) 2016-02-24
MX2016008108A (es) 2017-03-09
US10028995B2 (en) 2018-07-24
US20150164980A1 (en) 2015-06-18
US20220047669A1 (en) 2022-02-17
IL246162B (en) 2020-03-31
IL246162A0 (en) 2016-07-31
ES2771749T3 (es) 2020-07-07
SMT202500427T1 (it) 2026-01-12
LT3607962T (lt) 2026-01-12
US20160129072A1 (en) 2016-05-12
SI2986308T1 (sl) 2020-03-31
PT3607962T (pt) 2025-11-18
WO2015095535A9 (en) 2016-07-14
US20190328827A1 (en) 2019-10-31
EP2986308A4 (en) 2017-01-11
EA201691258A1 (ru) 2016-11-30
PL2986308T3 (pl) 2020-05-18

Similar Documents

Publication Publication Date Title
FI3607962T3 (fi) Angiotensiini ii yksin tai yhdistelmänä hypotension hoitoon
PH12018501903A1 (en) Methods of treating depression using orexin-2 receptor antagonists
MX2013010839A (es) Metodo para inhibir flt3 cinasa fosforilada constitutivamente activa.
WO2016004093A3 (en) Therapeutic compositions including galectin-3 inhibitors and uses thereof
ZA202002139B (en) Combination pharmaceutical agents as rsv inhibitors
MX2013012212A (es) Sistemas de bombeo de fluido medico y dispositivos y metodos relacionados.
FI3593817T3 (fi) Koostumus käytettäväksi likinäköisyyden ehkäisyssä tai vähentämisessä
EA201170018A1 (ru) Разагилин для изменения течения болезни паркинсона
EA201270221A1 (ru) Лечение болезни крона с применением лаквинимода
PH12015502275B1 (en) Therapuetic uses of empagliflozin
WO2012002687A3 (en) Methods for treating bipolar disorder
MX375476B (es) Composición farmacéutica que comprende empagliflozina, métodos para tratamiento y sus usos.
WO2009094194A3 (en) Diagnostic and therapeutic uses of gelsolin in renal failure
WO2011091225A3 (en) Alpha-2 adrenergic agonist having long duration of intraocular pressure-lowering effect
NZ600544A (en) Compositions and methods for the treatment of angiogenesis-related eye diseases
CA2914620C (en) Heterocyclic derivatives and use thereof
EA201400067A1 (ru) Новая терапевтическая композиция, содержащая апоморфин в качестве активного ингредиента
RU2019138024A (ru) ХЛОРИДНАЯ СОЛЬ ПЕПТИДА TAT-NR2B9c, КОМПОЗИЦИЯ НА ЕГО ОСНОВЕ И СПОСОБЫ ИХ ПОЛУЧЕНИЯ
WO2011159124A3 (ko) Ｉｎｔｅｒｌｅｕｋｉｎ-６ 억제 작용을 갖는 신규한 벤즈옥사졸 유도체, 이의 제조 방법 및 이를 포함하는 약학적 조성물
HK1223825A1 (zh) 包含阿曲生坦的稳定化药物剂型
JP2013504519A5 (enExample)
MX336477B (es) Derivado de aminoacido.
ZA202203563B (en) Pediatric suspension formulation
DK1732551T3 (da) Perhexilin til behandling af kronisk hjertesvigt
EA201100243A1 (ru) Композиции для лечения розацеи